Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study

Oral Oncology

Volumn 51, Issue 1, 2015, Pages 90-95

  Wolf, Gregory T ^a   Chepeha, Douglas B ^a   Bellile, Emily ^a   Nguyen, Ariane ^a   Thomas, Daffyd ^a   McHugh, Jonathan ^a   University of Michigan Head and Neck SPORE Program, ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Oral cavity cancer; Tumor associated macrophage; Tumor infiltrating lymphocytes

Indexed keywords

ALCOHOL; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; NATURAL KILLER CELL; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; SMOKING; TOBACCO; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; AGED; COHORT ANALYSIS; IMMUNOLOGY; MOUTH TUMOR; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS;

EID: 84920516915     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.09.006     Document Type: Article

References (53)

1. Huang TY, Hsu LP, Wen Y, et al. Predictors of locoregional recurrence in earl stage oral cavity cancer with free surgical margins. Oral Oncol 2010;46:49-55.
2. Duffy SA, Taylor J, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008;113(4):750-7.
3. Lee JJ, Chang YL, Lai WL, Ko JY, et al. Increased prevalence of interleukin-17-producing CD4+ tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 2011;33:1301-8.
4. high Fox p3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-54.
5. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;6:5904-12 (PMID 18836471).
6. Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010;32:946-58.
7. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9.
8. Mahmoud SMA, Paish EC, Powe DG, et al. Tumor infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
9. DeNardo DG, Brennan DJ, Reshapai E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery 2011;1L:54-76.
10. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2009;28:105-13.
11. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Krowmer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011;71:5601-5.
12. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009;9:65-75.
13. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011;60(7):909-18.
14. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue cancer. Arch Otolaryngol Head Neck Surg 1997;124:641-6.
15. Metelmann HR, Hyckel P, Podmelle F. Oral cancer treatment and immune targets - a role for dentritic cells? J Cranio-Max-Facial Surg 2012;40:103-4.
16. Upadhyay RB, Upadhyay J, Rao NN, Agrawal P. The role of Langerhans cells in oral squamous cell carcinoma. Chin-German J Clinical Oncol 2011;10:606-11.
17. Ohman J, Magnusson B, Telemos E, Jontell M, Hasseus EB. Langerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas-evidence for immunosurveillance. Scan J Immunol 2012;76:39-48.
18. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001;91:2136-47.
19. Wolf GT, Hudson JL, Peterson KA, et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986;95:142-52.
20. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72.
21. Marcus B, Arenberg D, Lee J, et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 2004;101:2779-87.
22. Wansom D, Light E, Thomas D, et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 2012;122:121-7.
23. + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 2008;8:57.
24. Loose D, Signore A, Bonanno E, Vermeersch H, Dierckx R, Deron P, et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biotherapy Radiopharm 2008;23(1):25-33.
25. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008;21:1527-32.
26. Halama N, Michel S, Kloor M, Zoenig I, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011;71:5670-7.
27. Ladoire S, Arnould L, Mignot G, Coudert B, Rébé C, Chalmin F, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;125(1):65-72.
28. Byrne WL, Mills KHG, Ledere JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011;71:6915-20.
29. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAS) for high-throughput molecular pathology research. Int J Cancer 2001;94:1-5.
30. Pretscher D, Distel LV, Grabenbauer GG, et al. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 2009;9:292-301.
31. Wolf GT, Carey TE. Tumor antigen phenotype, biologic staging and prognosis in head and necksquamous carcinoma. J Natl Cancer Inst Mongr 1992;13:67-74.
32. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009;4:e6562.
33. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39-51 (PMID: 0371344).
34. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, et al. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res 2011;1(17):7230-9.
35. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011;128:703-11.
36. Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011;6(4):e19495. http://dx.doi.org/10.1371/journal.pone.0019495.
37. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
38. Bonde AK, Tischler V, Kumare S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012;12:35.
39. Kunz-Schughart LA, Weber A, Rehli M, Gottfired E, Brockhoff G, Krause SW, et al. The, "classical" macrophage marker CD68 is strongly expressed in primary human fibroblasts. Verh Dtsch Ges Pathol 2003;87:215-23.
40. Esteban F, Ruiz-Cabello F, Gonzalez-Moles MA, Lopez-Gonzalez MA, Funez R, Redondo M. Clinical significance of Langerhans cells in squamous cell carcinoma of the larynx. J Oncol 2012:5. Article ID 753296.
41. Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, et al. Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013;2(10):e25771.
42. Chang KP, Kao HK, Yen TC, Chang YL, Liang Y, Liu SC, et al. Overexpression of macrophage inflammatory protein-3a in oral cavity squamous cell carcinoma is associated with nodal metastasis. Oral Oncol 2011;47:108-13.
43. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011;224(3):389-400.
44. highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11.
45. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-20.
46. Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T ce3lls in patients with head and neck cancer. Clin Cancer Res 2013;19:6585-96.
47. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 2007;29:120-7.
48. Wansom D, Light E, Worden F, et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010;136:1267-73.
49. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993;81:1607-16123.
50. Huang RR, Jalil J, Economou JS, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011;17:4101-9.
51. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010;19:711-23.
52. Agarwala SS, Ribas A. Current experience with CTLA4A-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010;33:557-69.
53. Beatty GL, Chiorean EG, Fishman MP, Saboury B, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.